Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 669-672

  Kapelski, Stephanie ^a,b   De Almeida, Melanie ^a,b   Fischer, Rainer ^a,b   Barth, Stefan ^a,c   Fendel, Rolf ^a,b  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANZYME B; GRANZYME B SINGLE CHAIN FV FUSION PROTEIN; HYBRID PROTEIN; UNCLASSIFIED DRUG; ANTIMALARIAL AGENT; GRANZYME; MEROZOITE SURFACE PROTEIN 4, PLASMODIUM; PARASITE ANTIGEN; PROTOZOAL PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIMALARIAL ACTIVITY; ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; COLORIMETRY; ENZYME ACTIVITY; HEMATOCRIT; HUMAN; IC50; MEROZOITE; NONHUMAN; PLASMODIUM FALCIPARUM; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG SENSITIVITY; HEK293 CELL LINE; PROCEDURES;

ANTIGENS, PROTOZOAN; ANTIMALARIALS; DRUG DELIVERY SYSTEMS; GRANZYMES; HEK293 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PARASITIC SENSITIVITY TESTS; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 84920169150     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04190-14     Document Type: Article

References (36)

1. WHO. 2013. World malaria report 2013. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/world -malaria-report-2013/wmr2013-no-profiles.pdf?ua=1.
2. Keeling PJ, Rayner JC. 25 June 2014. The origins of malaria: there are more things in heaven and earth. Parasitology. http://dx.doi.org/10.1017 /S0031182014000766.
3. Schwartz L, Brown GV, Genton B, Moorthy VS. 2012. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 11:11. http://dx.doi.org/10.1186/1475-2875-11-11.
4. Crompton PD, Pierce SK, Miller LH. 2010. Advances and challenges in malaria vaccine development. J Clin Invest 120:4168-4178. http://dx.doi .org/10.1172/JCI44423.
5. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ. 2009. Artemisinin resistance in Plasmodium falciparum malaria.NEngl J Med 361:455-467. http: //dx.doi.org/10.1056/NEJMoa0808859.
6. Mavoungou E, Luty AJ, Kremsner PG. 2003. Natural killer (NK) cellmediated cytolysis of Plasmodium falciparum-infected human red blood cells in vitro. Eur Cytokine Netw 14:134-142.
7. Böttger E, Multhoff G, Kun JF, Esen M. 2012. Plasmodium falciparuminfected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One 7:e33774. http://dx.doi.org/10.1371/journal .pone.0033774.
8. Solomon JB, Forbes MG, Solomon GR. 1985. A possible role for natural killer cells in providing protection against Plasmodium berghei in early stages of infection. Immunol Lett 9:349-352. http://dx.doi.org/10.1016 /0165-2478(85)90061-6.
9. Hermsen CC, Konijnenberg Y, Mulder L, Loé C, van Deuren M, van der Meer JW, van Mierlo GJ, Eling WM, Hack CE, Sauerwein RW. 2003. Circulating concentrations of soluble granzyme A and B increase during natural and experimental Plasmodium falciparum infections. Clin Exp Immunol 132:467-472. http://dx.doi.org/10.1046/j.1365-2249.2003 .02160.x.
10. Kreidenweiss A, Kremsner PG, Mordmüller B. 2008. Comprehensive study of proteasome inhibitors against Plasmodium falciparum laboratory strains and field isolates from Gabon. Malar J 7:187. http://dx.doi.org/10 .1186/1475-2875-7-187.
11. Stahnke B, Thepen T, Stöcker M, Rosinke R, Jost E, Fischer R, Tur MK, Barth S. 2008. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther 7:2924-2932. http://dx.doi.org/10.1158/1535-7163.MCT-08-0554.
12. Losasso V, Schiffer S, Barth S, Carloni P. 2012. Design of human granzyme B variants resistant to serpin B9. Proteins 80:2514-2522. http: //dx.doi.org/10.1002/prot.24133.
13. Schiffer S, Hansen HP, Hehmann-Titt G, Huhn M, Fischer R, Barth S, Thepen T. 2013. Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer J 3:e106. http://dx.doi.org/10.1038 /bcj.2013.4.
14. Surolia N. 2000. Receptor-mediated targeting of toxins to intraerythrocytic parasite Plasmodium falciparum. Adv Drug Deliv Rev 41:163-170. http://dx.doi.org/10.1016/S0169-409X(99)00063-0.
15. Surolia N, Misquith S. 1996. Cell surface receptor directed targeting of toxin to human malaria parasite, Plasmodium falciparum. FEBS Lett 396: 57-61. http://dx.doi.org/10.1016/0014-5793(96)01065-4.
16. Haldar K, Henderson CL, Cross GA. 1986. Identification of the parasite transferrin receptor of Plasmodium falciparum-infected erythrocytes and its acylation via 1,2-diacyl-sn-glycerol. Proc Natl Acad Sci U S A 83:8565-8569. http://dx.doi.org/10.1073/pnas.83.22.8565.
17. Rodriguez MH, Jungery M. 1986. A protein on Plasmodium falciparuminfected erythrocytes functions as a transferrin receptor. Nature 324:388-391. http://dx.doi.org/10.1038/324388a0.
18. Clark M, Fisher NC, Kasthuri R, Cerami Hand C. 2013. Parasite maturation and host serum iron influence the labile iron pool of erythrocyte stage Plasmodium falciparum. Br J Haematol 161:262-269. http://dx.doi .org/10.1111/bjh.12234.
19. Garcia Y, Puentes A, Curtidor H, Cifuentes G, Reyes C, Barreto J, Moreno A, Patarroyo ME. 2007. Identifying merozoite surface protein 4 and merozoite surface protein 7 Plasmodium falciparum protein family members specifically binding to human erythrocytes suggests a new malarial parasite-redundant survival mechanism. J Med Chem 50:5665-5675. http://dx.doi.org/10.1021/jm070773z.
20. Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, Kemp DJ, Coppel RL. 1997. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 65:4460-4467.
21. Drew DR, Sanders PR, Crabb BS. 2005. Plasmodium falciparum merozoite surface protein 8 is a ring-stage membrane protein that localizes to the parasitophorous vacuole of infected erythrocytes. Infect Immun 73: 3912-3922. http://dx.doi.org/10.1128/IAI.73.7.3912-3922.2005.
22. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA. 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172:379-382. http://dx.doi.org/10.1084/jem.172.1 .379.
23. Burns JM, Jr, Belk CC, Dunn PD. 2000. A protective glycosylphosphati-dylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains. Infect Immun 68:6189-6195. http://dx.doi.org/10.1128/IAI.68.11.6189 -6195.2000.
24. Boyle MJ, Langer C, Chan JA, Hodder AN, Coppel RL, Anders RF, Beeson JG. 2014. Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum. Infect Immun 82:924-936. http://dx.doi.org/10.1128/IAI.00866-13.
25. Durocher Y, Perret S, Kamen A. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspensiongrowing human 293-EBNA1 cells. Nucleic Acids Res 30:E9. http://dx.doi .org/10.1093/nar/30.2.e9.
26. Stöcker M, Tur MK, Sasse S, Krüssmann A, Barth S, Engert A. 2003. Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expr Purif 28:211-219. http: //dx.doi.org/10.1016/S1046-5928(02)00709-X.
27. Schiffer S, Letzian S, Jost E, Mladenov R, Hristodorov D, Huhn M, Fischer R, Barth S, Thepen T. 2013. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Lett 341:178-185. http: //dx.doi.org/10.1016/j.canlet.2013.08.005.
28. Remarque EJ, Faber BW, Kocken CH, Thomas AW. 2008. A diversitycovering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect Immun 76:2660-2670. http://dx.doi .org/10.1128/IAI.00170-08.
29. Noedl H, Bronnert J, Yingyuen K, Attlmayr B, Kollaritsch H, Fukuda M. 2005. Simple histidine-rich protein 2 double-site sandwich enzymelinked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother 49:3575-3577. http://dx.doi.org/10.1128 /AAC.49.8.3575-3577.2005.
30. Tur MK, Huhn M, Jost E, Thepen T, Brümmendorf TH, Barth S. 2011. In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA= in a human acute myeloid leukemia xenograft tumor model. Int J Cancer 129:1277-1282. http://dx.doi.org/10.1002/ijc.25766.
31. Huhn M, Sasse S, Tur MK, Matthey B, Schinköthe T, Rybak SM, Barth S, Engert A. 2001. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. Cancer Res 61:8737-8742. http://dx.doi.org/10.1016/S0959 -8049(01)80351-8.
32. Hristodorov D, Mladenov R, Pardo A, Pham AT, Huhn M, Fischer R, Thepen T, Barth S. 2013. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Br J Cancer 109:1570-1578. http://dx.doi .org/10.1038/bjc.2013.457.
33. Oberoi P, Jabulowsky RA, Bähr-Mahmud H, Wels WS. 2013. EGFRtargeted granzyme B expressed in NK cells enhances natural cytotoxicity and mediates specific killing of tumor cells. PLoS One 8:e61267. http://dx .doi.org/10.1371/journal.pone.0061267.
34. Liu Y, Cheung LH, Hittelman WN, Rosenblum MG. 2003. Targeted delivery of human pro-apoptotic enzymes to tumor cells: in vitro studies describing a novel class of recombinant highly cytotoxic agents. Mol Cancer Ther 2:1341-1350.
35. Meslin B, Barnadas C, Boni V, Latour C, De Monbrison F, Kaiser K, Picot S. 2007. Features of apoptosis in Plasmodium falciparum erythrocytic stage through a putative role of PfMCA1 metacaspase-like protein. J Infect Dis 195:1852-1859. http://dx.doi.org/10.1086/518253.
36. Bird CH, Sun J, Ung K, Karambalis D, Whisstock JC, Trapani JA, Bird PI. 2005. Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells. Mol Cell Biol 25:7854-7867. http://dx .doi.org/10.1128/MCB.25.17.7854-7867.2005.